Investigating the Effects of Dietary Nitrate on Vascular Function, Platelet Reactivity and Restenosis in Stable Angina (NITRATE-OCT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02529189 |
Recruitment Status :
Recruiting
First Posted : August 20, 2015
Last Update Posted : August 23, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cardiovascular Diseases | Dietary Supplement: Beetroot Juice | Phase 2 |
To address the aims a proof-of-concept study will be conducted to ascertain whether a dietary nitrate approach might prove useful adjunctive therapy improving vascular function in patients with stable angina post elective angioplasty.
Design: A prospective randomised, single-centre, double-blind, placebo-controlled trial
Setting: Patients with stable angina and single/multiple coronary artery stenosis undergoing elective percutaneous coronary intervention (PCI) who are haemodynamically stable (systolic BP>100 mmHg). These patients will be recruited at The Barts Health Heart Centre, based at St. Bartholomew's Hospital. This is one of the biggest centres in the United Kingdom, serving a population of almost two million people from The City of London and The North East up to the M25 and is a 24/7 centre performing approximately 2000 non-primary angioplasties a year.
The study will take place in the Clinical Trials Unit, William Harvey Heart Centre.
Target population: A total of 246 patients (male and female, age 18-85) with stable angina as per requirements indicated above. Follow-up will take place in the Clinical Trials Unit, William Harvey Research Institute.
Treatment: Patients will be randomised (using an on line randomisation database) to receive 70 ml of a beetroot juice concentrate containing 4-5 mmol nitrate or nitrate-deplete placebo juice concentrate. This intervention will be taken by the patient daily from one day prior to re-establishment of flow with PCI and stent implantation.
Analysis: We will analyse the results based on an intention to treat analysis. We will also carry out further per protocol analyses and a subgroup analysis on patients who are on organic nitrates as part of their routine therapy and a comparison of DES (drug-eluting stents) versus BMS (bare-metal stents).
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 246 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomised, Double-blind, Placebo-controlled Study Investigating the Effects of Dietary Nitrate on Vascular Function, Platelet Reactivity and Restenosis in Stable Angina |
Actual Study Start Date : | November 2015 |
Estimated Primary Completion Date : | April 2019 |
Estimated Study Completion Date : | April 2021 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Nitrate-rich beetroot juice
70 ml of a beetroot juice concentrate containing ~5 mmol nitrate
|
Dietary Supplement: Beetroot Juice
70 ml of beetroot juice containing ~5 mmol of inorganic nitrate |
Placebo Comparator: Nitrate-deplete beetroot juice
70 ml of a beetroot juice concentrate that is nitrate-depleted
|
Dietary Supplement: Beetroot Juice
70 ml of beetroot juice which is nitrate-depleted |
- Difference between groups in In-stent late loss, where late loss is defined as the difference between the minimum luminal diameter (MLD). [ Time Frame: 6 months +/- 1 month post intervention ]
- Difference from baseline within the group and between groups in endothelial function assessed by flow-mediated dilatation of the brachial artery at 6 months compared to pre-procedure assessment. [ Time Frame: 6 months and 12 months post intervention ]
- Difference from baseline within the group and between groups in target vessel revascularisation (TVR). [ Time Frame: 6 months post intervention ]
- Difference from baseline within the group and between groups in restenosis rate (diameter >50%). [ Time Frame: 6 months post intervention ]
- Difference from baseline within the group and between groups in in-segment late loss. [ Time Frame: 6 months post intervention ]
- Difference from baseline between groups in major adverse cardiac events (i.e. Myocardial Infarction, death, Cerebrovascular Accident, Target Vascular Revascularisation). [ Time Frame: 6 months, 12 months and 24 months post intervention ]
- Difference from baseline within the group and between groups in inflammatory markers. [ Time Frame: 6 months and 12 months post intervention ]
- Difference from baseline within the group and between groups in plasma and erythrocyte nitrite reductase. [ Time Frame: 6 months and 12 months post intervention ]
- Difference from baseline within the group and between groups in changes in plasma xanthine oxidase activity. [ Time Frame: 6 months and 12 months post intervention ]
- Difference from baseline within the group and between groups high-sensitivity C-reactive protein (hsCRP). [ Time Frame: 6 months and 12 months post intervention ]
- Difference from baseline within the group and between groups in Interleukin-6 (IL-6). [ Time Frame: 6 months and 12 months post intervention ]
- Difference from baseline within the group and between groups in platelet activation (P-Selectin and platelet-monocyte aggregates). [ Time Frame: 6 months and 12 months post intervention ]
- Difference from baseline within the group and between groups in platelet aggregation ex vivo (ADP, collagen, arachidonic acid). [ Time Frame: 6 months and 12 months post intervention ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with stable angina diagnosed by a cardiologist on optimal medical therapy undergoing angioplasty to treat residual symptoms.
- Aged 18-85
- Patients able and willing to give their written informed consent.
- Patients undergoing successful PCI procedure.
Exclusion Criteria:
- Unstable ischaemic heart disease, with an episode of chest pain in less than 24 hours.
- Patients who have had previous coronary artery bypass surgery (CABG), if they are undergoing angioplasty within a non-native vessel.
- Patients undergoing angioplasty with a bio-absorbable stent.
- Current diagnosis of or treatment for malignancy, other than non-melanoma skin cancer.
- Current life-threatening condition other than vascular disease that may prevent a subject completing the study.
- Use of an investigational device or investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication.
- Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures).
- Severe acute infection, or significant trauma (burns, fractures).
- Pregnancy. This will be tested by urine human chorionic gonadotropin (hCG) measurement
- History of alcohol or drug abuse within the past 6 months.
- A history of heart failure New York Heart Association (NYHA) class 3-4 or severe left ventricular dysfunction (left ventricular ejection fraction of <30%) regardless of symptom status.
- Systemic autoimmune disease such as rheumatoid arthritis, connective tissue disease, or other conditions known to be associated with chronic inflammation such as inflammatory bowel disease.
- Patients who have donated > 500mls blood within 56 days prior to study medication administration.
- Anaemia with Hb <10g/dl, or any other known blood disorder or significant illness that may affect platelet function, and coagulation.
- A history of chronic viral hepatitis (including presence of hepatitis B surface antigen or hepatitis C antibody or other chronic hepatic disorder) or HIV.
- Abnormal liver function due to acute or chronic liver conditions 3 x upper limit of normal at screening.
- Renal impairment with creatinine clearance (eGFR) of 35ml/min at screening.
- If patients are on mouthwash, they must be willing to stop using this at least 1 week before the start of the study and throughout the duration that they are involved in the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02529189
Contact: Amrita Ahluwalia, BSc PhD | a.ahluwalia@qmul.ac.uk | ||
Contact: Anthony Mathur, MB BChir PhD | a.mathur@qmul.ac.uk |
United Kingdom | |
William Harvey Research Institute, Barts and The London School of Medicine | Recruiting |
London, United Kingdom, EC1M 6BQ | |
Contact: Amrita Ahluwalia, BSc, PhD k.s.rathod@qmul.ac.uk | |
Contact: Krishnaraj Rathod, MBBS k.s.rathod@qmul.ac.uk | |
Principal Investigator: Anthony Mathur, MB BChir PhD | |
Sub-Investigator: Krishnaraj S Rathod, MBBS | |
Sub-Investigator: Daniel A Jones, MBBS PhD | |
Sub-Investigator: Amy Robertson, BSc | |
Sub-Investigator: Shanti Velmurugan, MBBS PhD |
Principal Investigator: | Amrita Ahluwalia, PhD | Queen Mary University of London |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Amrita Ahluwalia, Principal Investigator Investigator: Amrita Ahluwalia [aahluwalia] Official Title: Deputy Director of The William Harvey Research Institute, Prof of Vascular Pharmacology, Queen Mary University of London |
ClinicalTrials.gov Identifier: | NCT02529189 |
Other Study ID Numbers: |
15/LO/0555 |
First Posted: | August 20, 2015 Key Record Dates |
Last Update Posted: | August 23, 2018 |
Last Verified: | August 2018 |
Stable Angina Angioplasty Optical Coherence Tomography Nitrate |
Cardiovascular Diseases Angina, Stable Angina Pectoris Myocardial Ischemia Heart Diseases |
Vascular Diseases Chest Pain Pain Neurologic Manifestations |